Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Clinical trial NCT02092909 · TERMINATED
Trial details
- NCT number
- NCT02092909
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2017-04-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.